Skip to main content

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly

Journal of Endocrinological Investigation volume 22, pages 40–47 (1999)Cite this article

Abstract

This single-center open sequential study aimed at comparing the efficacy of a 6-month treatment with lanreotide (LAN) (60-90 mg/month im), to that of octreotide (OCT) (0.3-0.6 mg/day sc) in 45 patients with active acromegaly (GH, 63.2±12.1 ng/ml, IGF-I, 757±67.1 ng/ml). After 6 months of OCT treatment, safe GH (fasting <2.5, glucose suppressed <1 ng/ml) and IGF-I (normalized for age) levels were achieved in 23 patients. After treatment withdrawal, GH levels significantly increased in all patients, though remaining slightly lower than pre-OCT therapy (39.2±5.8 ng/ml) while plasma IGF-I levels were unchanged (654±59.4 ng/ml). After 6 months of LAN treatment, safe GH and IGF-I levels were achieved in 26 patients (57.7%). After OCT or LAN treatments, no significant difference was found between nadir GH (6±1 vs 5.9±1.1 ng/ml) and IGF-I levels (281±23.3 vs 262±20.6 ng/ml). Four out of the 20 patients poorly responsive to OCT achieved safe GH and IGF-I levels after LAN treatment. Among the 20 non-operated patients, a significant tumor shrinkage was documented by CT and/or MRI in 5 patients after OCT and in 1 patient after LAN treatment. All patients referred a notable improvement of soft tissue swelling, arthralgia, headache and weakness, both after OCT and LAN treatments. During the first days of OCT treatment, abdominal discomfort was referred by 12 patients and steatorrhea by 5 patients: side effects disappeared spontaneously in 6 cases while during treatment with pancreatic enzymes in the remaining ones. After the first injections of LAN, abdominal discomfort was referred by 10 patients and steatorrhea by 2 of them. No difference in the prevalence of both early and late side effects was noted after treatment with OCT and LAN (χ2, 0.49). The majority of these poorly tolerant patients had side effects with both compounds. During LAN treatment, side effects were mild and spontaneously disappeared but recurred after the injection of the drug in six patients. Gallstones were detected in one patient during OCT and in another during LAN, sludge was noted in 6 patients after OCT and in 2 after LAN treatment. In conclusion, the treatment with LAN allowed to achieve safe GH and IGF-I levels in 57.7% of acromegalics with an excellent patients’ compliance. LAN treatment possessed similar efficacy and caused side effects with a similar incidence of OCT treatment. The recurrence of side effects after LAN injection suggests the necessity of a careful monitoring of adverse reactions.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Melmed S. Acromegaly Engl. J. Med. 322: 966, 1990.

    Article  CAS  Google Scholar 

  2. Frohman L.A. Therapeutic options in acromegaly. J. Clin. Endocrinol. Metab. 72: 1175, 1991.

    PubMed  Article  CAS  Google Scholar 

  3. Melmed S., Ho K., Klibanski A., Reichlin S., Thorner M. Recent advances in pathology, diagnosis and management of acromegaly. J. Clin. Endocrinol. Metab. 80: 3395, 1995.

    PubMed  CAS  Google Scholar 

  4. Clayton R.N. New developments in the management of acromegaly. Should we achieve absolute biochemical cure? J. Endocrinol. 155: S23, 1997.

    PubMed  CAS  Google Scholar 

  5. Melmed S., Dowling H., Frohman L., Ho K., Lamberts S.W.J., LaMont J.T., Sassolas G., Schoenfield L., Snyder PJ., Wass J.A.H. Consensus statement: benefits versus risks of medical therapy for acromegaly. Am. J. Med. 97: 468, 1994.

    Article  Google Scholar 

  6. Lamberts S.W.J., van Der Lely A.J., de Herder W.W., Hofland J. Octreotide. N. Engl. J. Med. 334: 246, 1996.

    PubMed  Article  CAS  Google Scholar 

  7. Sassolas G., Harris A.G., James-Deidier A. Long-term effect of incremental doses of the soma-tostatin analog SMS 201-995 in 58 acromegalic patients. J. Clin. Endocrinol. Metab. 71: 391, 1990.

    PubMed  Article  CAS  Google Scholar 

  8. Vance M.L., Harris A.G. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch. Intern. Med. 151: 1573, 1991.

    PubMed  Article  CAS  Google Scholar 

  9. Newmann C.B., Melmed S., Snyder P.J., Young W.F., Boyajy L.D., Levy R., Stewart W.N., Klibanski A., Molitch M.E., Gagel R.F. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. J. Clin. Endocrinol. Metab. 80: 2768, 1995.

    Google Scholar 

  10. Arosio M., Macchelli S., Rossi C.M., Casati G., Biella O., Faglia G. Effects of treatment with octreotide in acromegalic patients-a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur. J. Endocrinol. 133: 430, 1995.

    PubMed  Article  CAS  Google Scholar 

  11. Heron I., Thomas F., Dero M., Gancel A., Ruiz J.M., Schatz B., Kuhn J.M. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J. Clin. Endocrinol. Metab. 76: 721, 1993.

    PubMed  CAS  Google Scholar 

  12. Caron P., Morange-Ramos I., Cogne M., Jaquet P. Three years follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J. Clin. Endocrinol. Metab. 82: 18, 1997.

    PubMed  CAS  Google Scholar 

  13. Giusti M., Gussoni G., Cuttica C.M., Giordano G., and the italian multicenter slow-release lanreotide study group. Effectiveness and tolerability of slow-release lan-reotide treatment in active acromegaly: six-month report on a italian multicenter study. J. Clin. Endocrinol. Metab. 81: 2089, 1996.

    PubMed  CAS  Google Scholar 

  14. Marek J., Hana V., Krsek M., Justova V., Catus F., Thomas F. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur. J. Endocrinol. 131: 20, 1994.

    PubMed  Article  CAS  Google Scholar 

  15. Morange I., De Boisvilliers F., Chanson P., Lucas B., Dewailly D., Catus F., Thomas F., Jaquet P. Slow-release lanreotide treatment in acromegalic patients previously normalized by octreotide. J. Clin. Endocrinol. Metab. 79: 145, 1994.

    PubMed  CAS  Google Scholar 

  16. Chiodini P.G., Attanasio R., Cozzi R., Dallabonzana D., Oppizzi G., Orlandi P., Strada S., Liuzzi A. CV 205–502 in acromegaly. Acta Endocrinol. (Copenh.) 128: 389, 1993.

    CAS  Google Scholar 

  17. Lombardi G., Colao A., Ferone D, Sarnacchiaro F., Marzullo P., Di Sarno A., Rossi E., Merola B. CV 205-502 treatment in therapy-resistant acrome-galic patients. Eur. J. Endocrinol. 132: 559, 1995.

    PubMed  Article  CAS  Google Scholar 

  18. Colao A., Ferone D., Marzullo P., Di Sarno A., Cerbone G., Sarnacchiaro F., Cirillo S., Merola B., Lombardi G. Effect of different dopaminergic agents in the treatment of acromegaly. J. Clin. Endocrinol. Metab. 82: 518, 1997.

    PubMed  Article  CAS  Google Scholar 

  19. Ferrari C., Paracchi A., Romano C., Gerevini G., Boghen M., Barreca A., Fortini P., Dubini A. Long-lasting lowering of serum growth hormone and prolactin levels by single or repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin. Endocrinol. (Oxf.) 29: 467, 1988.

    Article  CAS  Google Scholar 

  20. Jackson S.N.J., Fowler J., Howlett T.A. Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin. Endocrinol. (Oxf.) 46: 745, 1997.

    Article  CAS  Google Scholar 

  21. Abs R., Versholst J., Maiter D., et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. 83: 374, 1998.

    PubMed  Article  CAS  Google Scholar 

  22. Bevan J.S., Webster J., Burke C.W., Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 13: 220, 1992.

    PubMed  Article  CAS  Google Scholar 

  23. Chiodini P.G., Cozzi R., Dallabonzana D., Oppizzi G., Verde G., Petroncini M., Liuzzi A., Del Pozo E. Medical treatment of acromegaly with SMS 201-995, a somatostatin analogue: a comparison with bromocriptine. J. Clin. Endocrinol. Metab. 64: 447, 1987.

    PubMed  Article  CAS  Google Scholar 

  24. Fløgstad A.K., Halse J., Grass P., Abish E., Djøseland O., Kutz K., Bodd E., Jervell J. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J. Clin. Endocrinol. Metab. 79: 461, 1994.

    PubMed  Google Scholar 

  25. Lamberts S.W.J., Zweens M., Verschoor L., del Pozo E. A comparison among the growth hormone lowering effect of the somatostatin analog, SMS 201-995, bromocriptine and combination of both drugs. J. Clin. Endocrinol. Metab. 63: 16, 1986.

    PubMed  Article  CAS  Google Scholar 

  26. Fløgstad A.K., Halse J., Bakke S., Lancranjan I., Marbach P., Bruns Ch., Jervell J. Sandostatin LAR in acromegalic patients: long-term treatment. J. Clin. Endocrinol. Metab. 82: 23, 1997.

    PubMed  Article  Google Scholar 

  27. Lancranjan I., Bruns C., Grass P., Jaquet P., Jervell J., Kendall-Taylor P., Lamberts S.W., Marbach P., Orskov H., Pagani G., Sheppard M., Simionescu L. Sandostatin-LAR®: a promising therapeutic tool in the management of acromegalic patients. Metabolism 45: 67, 1996.

    PubMed  Article  CAS  Google Scholar 

  28. Gillis J.C., Noble S., Goa K.L. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 53: 681, 1997.

    PubMed  Article  CAS  Google Scholar 

  29. Colao A., Ferone D., Lastoria S., Marzullo P., Cerbone G., Di Sarno A., Longobardi S., Merola B., Salvatore M., Lombardi G. Prediction of efficacy of octreotide therapy in patients with acromegaly. J. Clin. Endocrinol. Metab. 81: 1356, 1996.

    Google Scholar 

  30. Colao A., Merola B., Ferone D., Lombardi G. Acromegaly. J. Clin. Endocrinol. Metab. 82: 2777, 1997.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Molecular and Clinical Endocrinology and Oncology, “Federico II” University, via S. Pansini 5, 80131, Napoli, Italy

    A. Colao M.D., Ph.D., P. Marzullo, D. Ferone, V. Marinò, R. Pivonello, C. Di Somma, A. Di Sarno, A. Giaccio & G. Lombardi

Authors
  1. A. Colao M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Marzullo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Ferone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Marinò
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Pivonello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Di Somma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Di Sarno
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Giaccio
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Colao, A., Marzullo, P., Ferone, D. et al. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 22, 40–47 (1999). https://doi.org/10.1007/BF03345477

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345477

Key-words

  • GH, IGF-I
  • acromegaly
  • pituitary adenomas
  • somatostatin analogs
  • octreotide
  • lanreotide